<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02479100</url>
  </required_header>
  <id_info>
    <org_study_id>RADIOL/2015/CONTEND</org_study_id>
    <nct_id>NCT02479100</nct_id>
  </id_info>
  <brief_title>Contrast Enhanced Spectral Mammography (CESM) Study</brief_title>
  <acronym>CONTEND</acronym>
  <official_title>An Assessment of the Impact of CONTrast ENhanceD Mammography (CESM) on Patient Management and Comparison With MRI (CONTEND Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cambridge University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine if the addition of Contrast Enhanced Spectral
      Mammography (CESM) to standard diagnostic imaging, results in a decision regarding patient
      management - discharge, follow-up, surgery or treatment - being made sooner than it would if
      the patient had followed the standard course of investigations and review.

      The investigators also intend to compare CESM with MRI. Images and pathology results from
      patients who undergo both CESM ans MRI will be reviewed retrospectively for detection of
      abnormality and identification of type of abnormality, i.e. is it a cancer or not?
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of impact the addition of CESM has on patient management - does this lead to an earlier diagnosis / treatment plan</measure>
    <time_frame>Retospective analysis at end of data collection period ( approximately I year)</time_frame>
    <description>The pathway of each participant through the diagnostic process will be reviewed at the end of the data collection period to assess whether the addition of CESM resulted in a definitive decision regarding treatment being made earlier than in the usual diagnostic route.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>CESM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive CESM in addition to standard diagnostic procedures</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Contrast Enhanced Spectral Mammography</intervention_name>
    <arm_group_label>CESM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be willing and able to give written informed consent for participation in the study.

          -  Have a lesion of suspicion 3, 4 or 5 following mammography and ultrasound.

        Exclusion Criteria:

          -  Known or suspected pregnancyBreast implant

          -  Previous breast cancer

          -  Known renal impairment

          -  History of anaphylactoid or anaphylactic reaction to any contrast media

          -  Contrast media within 24 hours prior to CESM

          -  Commencement of neo-adjuvant chemotherapy, hormone treatment, radiotherapy or surgery
             for this episode
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fiona J Gilbert, FRCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cambridge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fiona D Gilbert</last_name>
    <phone>01223746439</phone>
    <email>fjg28@cam.ac.uk</email>
  </overall_contact>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2015</study_first_submitted>
  <study_first_submitted_qc>June 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2015</study_first_posted>
  <last_update_submitted>December 31, 2015</last_update_submitted>
  <last_update_submitted_qc>December 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cambridge</investigator_affiliation>
    <investigator_full_name>Professor Fiona J Gilbert</investigator_full_name>
    <investigator_title>Professor of Radiology, Department Head</investigator_title>
  </responsible_party>
  <keyword>Contrast Enhanced Spectral Mammography</keyword>
  <keyword>Breast</keyword>
  <keyword>Cancer</keyword>
  <keyword>Diagnosis</keyword>
  <keyword>Patient management</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

